echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > It’s all about delivery-antibodies improve nanoparticle delivery of therapeutic nucleic acids

    It’s all about delivery-antibodies improve nanoparticle delivery of therapeutic nucleic acids

    • Last Update: 2021-11-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    Image: Antibody-guided Nanoparticle Delivery System

    Source: Baylor College of Medicine

    Studies have shown that some nucleic acids, such as messenger RNA (mRNA), DNA and related molecules, can effectively treat diseases in a laboratory environment.


    "Currently, some TNAs have been approved for clinical use, and clinical trials are ongoing," said Changyi Johnny Chen, Ph.


    When naked nucleic acids enter the human body, they encounter some obstacles that limit their availability


    Although these obstacles limit their applications, TNAs are a promising method for the treatment of various diseases


    Liposomes are one of the most widely used delivery systems.


    LGA-PEI nanoparticles

    Since they moved to Baylor in 2002, the laboratory of Dr.


    Chen said: "Our previous research has shown that certain RNAs, such as microRNA-198 (miR-198), a natural tumor suppressor, may have clinical applications in cancer


    "For many years, my laboratory has been developing the TNA delivery system," Chen said


    The LGA-PEI polymer spontaneously forms nanoparticles, and the nanoparticle layer is wrapped with TNAs (such as miR-198) to protect them from enzymatic hydrolysis and enhance cellular uptake


    "Our results are encouraging, but we still want to further improve our delivery system," Chen said


    Antibodies improve delivery

    Antibodies are proteins produced by the immune system that can recognize and bind to specific markers on the cell surface


    For example, Chen and other researchers previously discovered that mesothelin (MSLN) is abundantly expressed in some human cancers, including pancreatic cancer


    "In the current study, we have successfully linked fragment antibodies against MSLN to our LGA-PEI polymer, and used fluorescent tags to show improved MSLN targeted metastasis in pancreatic cancer cells grown in laboratories and animal models.


    The Chen laboratory is interested in conducting research to test that this active targeted drug delivery system can inhibit tumor growth and metastasis and improve the overall survival of tumor-bearing animals compared with passive targeted drug delivery or other non-targeted drug delivery systems.


    The improved nanoparticle delivery system is a technology platform that can be extended to other types of cancer or diseases to develop new treatment methods, molecular diagnostic strategies or vaccines


    DOI

    10.
    3390 / ph14090841


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.